SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.

Pace, D; Khatami, A; Attard-Montalto, S; Voysey, M; Finn, A; Faust, SN; Heath, PT; Borrow, R; Snape, MD; Pollard, AJ (2016) Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine, 34 (50). pp. 6350-6357. ISSN 1873-2518 https://doi.org/10.1016/j.vaccine.2016.10.038
SGUL Authors: Heath, Paul Trafford

[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (47kB)
[img] Microsoft Word (.docx) (Article Highlights) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (12kB)
[img] Microsoft Word (.docx) (Figures) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (400kB)
[img] Microsoft Word (.docx) (Tables) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (24kB)

Abstract

BACKGROUND: Use of a polysaccharide vaccine challenge to demonstrate immunologic memory after priming with capsular group C meningococcal conjugate vaccines (MenCC) risks induction of immunologic hyporesponsiveness. For this reason, MenCC vaccines are now used as probes of immunologic memory, however, no studies have demonstrated their ability to distinguish primed from unprimed children. METHODS: This study was part of a randomised controlled trial investigating the immunogenicity of a booster dose of the combined Haemophilus influenzae type b and MenC-tetanus toxoid vaccine (Hib-MenC-TT) in infants receiving reduced dose MenCC vaccine priming schedules (one MenC-CRM/MenC-TT or two MenC-CRM vaccine doses) compared with an unprimed group. Antibody kinetics were studied in a subset of 269 children by measuring changes in the MenC serum bactericidal antibody, using rabbit complement, (MenC rSBA) titres and MenC specific IgG memory B-cells before and at 6 and 28days following the 12month booster vaccination. RESULTS: At 6days after the 12monthMenCC vaccine, the rise in MenC rSBA titres and MenC specific IgG memory B-cells of the primed groups were significantly higher than the infant MenCC naïve group. Participants primed with one MenC-TT dose had the highest increase in MenC rSBA titres compared with all other groups. The MenC rSBA titres at the 28th compared with the 6th day after boosting was significantly higher in those primed with a single MenC-TT/MenC-CRM vaccine in infancy compared with those who were not primed or who were primed with two doses of the MenC-CRM vaccine. CONCLUSION: Immunologic memory can be demonstrated by a MenCC booster vaccination but is affected by the type and number of MenCC doses used for infant priming. The MenC rSBA responses can be used to demonstrate successful immunologic priming.

Item Type: Article
Additional Information: © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: Capsular group C N. meningitidis, Immunologic memory, MenC glycoconjugate vaccines, MenC infant priming, Capsular group C N. meningitidis, Immunologic memory, MenC glycoconjugate vaccines, MenC infant priming, Capsular group C N. meningitidis, Immunologic memory, MenC glycoconjugate vaccines, MenC infant priming, Virology, 06 Biological Sciences, 07 Agricultural And Veterinary Sciences, 11 Medical And Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Vaccine
ISSN: 1873-2518
Language: eng
Dates:
DateEvent
7 December 2016Published
28 October 2016Published Online
18 October 2016Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 28029540
Web of Science ID: WOS:000390622600037
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108581
Publisher's version: https://doi.org/10.1016/j.vaccine.2016.10.038

Actions (login required)

Edit Item Edit Item